GSK3532795 blocks the protease enzyme, essential for the maturation and replication of HIV, playing a key role in highly active antiretroviral therapy (HAART).
Molecular Weight
691.02
Molecular Formula
C42H62N2O4S
Form
Lyophilized powder
Purity
≥98%
Identity
Confirmed by NMR/HPLC/MS.
Applications
GSK3532795 is researched as a next-generation HIV protease inhibitor, focusing on its potential to overcome resistance limitations in antiretroviral therapy.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
